

Assessment of proliferating activity in Paget's disease of the nipple by double stain immunohistochemistry

F. Buxant¹, I. Fayt², J.C. Noel²

Departments of Gynecology¹, and Pathology², Erasme Hospital, Free University of Brussels (ULB), Brussels (Belgium)

Summary

Paget disease of the nipple is a rare disease characterized by the presence of malignant glandular cells within the squamous epithelium of the nipple. The most common hypothesis to explain the development of Paget's disease is an intraepithelial epidermotropic migration of malignant epithelial cells originating from an underlying intraductal carcinoma. Although the immunohistochemical properties of Paget cells in the nipple have been extensively studied, their proliferating characteristics remain paradoxically poorly studied. In the present study we have investigated the proliferating activity of Paget cells in the nipple by using double stain immunohistochemistry with both Ki-67 (a protein which is expressed in all active parts of the cell cycle) and cytokeratin 7 (a highly sensitive marker of Paget cells). Ten cases of Paget's disease and the associated intraductal carcinomas (n = 10) and/or invasive carcinomas (n = 4) were tested. The mean Ki-67 index was in Paget's disease (26% ± 10), in intraductal carcinomas (23% ± 8) and/or in invasive carcinomas (20% ± 8) ($p > 0.05$). This is the first report to convincingly demonstrate by specific double stain immunohistochemistry that Paget's disease and underlying intraductal carcinomas share a close proliferating activity.

Key words: Paget's disease; Nipple; Breast; Proliferation; Ki-67; Double stain immunohistochemistry.

Introduction

Paget's disease of the nipple is a rare disease of the breast characterized by the presence of malignant glandular cells within the squamous epithelium of the nipple [1-3]. Clinically, the classical manifestation of Paget disease ranges from local reddening to eczematous or psoriasiform lesion of the nipple, soon extending to the mammary areola and then to the surrounding skin [1-3]. Paget's disease (PD) is almost always associated with underlying intraductal carcinoma of the lactiferous duct and more rarely with invasive carcinoma deep in the underlying breast [4-6]. Two majors hypotheses have been suggested for the development of PD. Firstly, it may represent an intraepithelial epidermotropic migration of the malignant epithelial cells from the intraductal carcinoma to the nipple. Secondly, for certain authors, failure to detect underlying carcinoma in a small number of cases, suggests that PD may result from situ neoplastic transformation of multi-potential cells present in the basal layer of the epidermis [1-3, 7-11]. If the immunohistochemical properties of Paget cells in the nipple have been extensively studied, their proliferating characteristics remain poorly understood because to assess more specifically the proliferating activity in the Paget's cells and not in the adjacent keratinocytes remains conflictual [12]. To clarify the issue, we used double stain immunohistochemistry with both cytokeratin 7 (CK 7) and Ki-67. CK 7 is a well recognized and highly sensitive marker of Paget cells and KI-67 is a human nuclear protein, which is expressed in all active parts of the cell cycle G1, S, G2 and mitosis but is absent in resting and quiescent cells (G0) [13-15]. The Ki-67 proliferating index of Paget cells

has been compared with those of underlying intraductal carcinomas and/or invasive carcinomas.

Material and Method

Ten cases of Paget disease were retrieved from the surgical pathology department of Erasme University Hospital and the material was collected according with the rules of the local ethical committee. All the patients were female. The mean age was 68 years (range 44-90). The clinical data which were available from the dermatology department consisted of an erythematous rash and/or eczematous-psoriasiform lesions of the nipple with extension to the areola in four patients (Figure 1). In all the patients, underlying ductal intraepithelial neoplasia grade 2 or 3 (DIN 2-3 according to the WHO 2003) were present. In addition, in four patients (3/8: 37%), invasive ductal carcinoma was also present (three grade 2 invasive carcinomas and one grade 3 invasive carcinoma according to the semi-quantitative method for assessing breast carcinoma from Elston and Ellis) [16].




Figure 1. — Typical clinical features of Paget's disease. Eczematiform reddening aspect of the nipple.

Revised manuscript accepted for publication January 26, 2009




Figure 2. — Double immunostaining of Paget cells with cytokeratin 7 (membranous and cytoplasmic staining - light) and Ki-67 (nuclear staining - dark).

Immunohistochemistry for double stain

For the quantification of proliferating endothelial cells, a Ki-67/CK7 double-labelling immunohistochemical staining was performed by using the EnVision G/2 double stain system (DAKO, Glostrup, Denmark). A monoclonal antibody directed against Ki-67 (clone MIB-1, dil 1:50, DAKO, Glostrup, Denmark) was applied to rehydrated paraffin sections and allowed to incubate for one hour at room temperature. Endogenous peroxidase was blocked. A secondary antibody linked to peroxidase and DAB was used to visualize the binding of the first antibody. The sections were then incubated for one hour with an antibody against CK 7 (clone OV-TL 12/30, dil 1:100, BioGenex, San Ramon, CA, USA). Alkaline phosphatase linked to a secondary antibody and fuchsin as a substrate chromogen system were used to complete the second immunostain.

The slides were examined for Ki-67 reactivity under x 20 objective by two independent observers who were blinded to outcome. A minimum of 300 nuclei per case of Paget disease and 500 nuclei for DIN 2-3 and invasive ductal carcinoma were counted. There was agreement between observers in more than 90 of cases but disagreements in evaluation were resolved by review and discussion at a multiheaded microscope.

Statistical analysis

Comparison of the data was performed using the Student's t-test (two-tailed). Statistical significance was defined as $p < 0.05$.




Figure 3 — Histogram showing Ki-67 index \pm SD in Paget's disease of the nipple and corresponding intraductal or invasive carcinoma.

Results

The Paget cells showed a strong immunoreactivity both for CK 7 and Ki-67 (Figure 2).

The mean Ki-67 index was higher in PD (26 % \pm 10) than in underlying intraductal carcinomas (23% \pm 8) and/or in invasive carcinomas (20% \pm 8) (Figure 3) ($p > 0.05$).

Discussion

Paget disease of the breast is rare and occurs in about 1% of all the patients with breast cancer [1-3]. In this disease, the epidermis of the nipple is invaded by large neoplastic cells presumed to originate from underlying in situ intraductal carcinoma. Indeed, considerable evidence demonstrates that immunohistochemically Paget cells show similar properties to the underlying intraductal carcinoma cells with a positivity for CK 7, low molecular weight cytokeratin, carcinoembryonic antigen, epithelial membrane antigen, HER2/NEU protein and p16 protein in a vast majority of cases [1-3, 10, 11, 17]. The attraction of Paget cells to epidermis has been explained by the fact that normal epidermal cells produce heregulin-alpha, a motility factor which exerts a chemotactic effect on Paget cells previously proved to express heregulin receptors HER2/NEU as well as HER3 and/or HER4, both of which function as co-receptors of HER2/NEU [7, 8].

The proliferating activity of Paget cells remains conflictual probably because by their nature they are entrapped among non neoplastic squamous cells in the epidermis rendering difficult the analysis of proliferating cells with classical immunohistochemistry for an individual antibody such as Ki-67 [12]. The only publication done on the subject described a Ki-67 index ranging from 16 to 19% but with a high standard deviation (\pm 28%) rendering the interpretation of the results extremely difficult. In addition no comparison between the Ki-67 index and underlying intraductal or invasive carcinomas was performed. The use of double stain immunohistochem-

istry with CK 7 and Ki-67 ensures an increase of specificity because CK 7 is an effective marker for Paget cells [1-3]. In the present study, we have shown that Paget cells are not only able to demonstrate migratory properties but also proliferating capacities and interestingly the proliferation Ki-67 index in PD is relatively similar to those of underlying intraductal carcinoma. Naturally, our data should be carefully thought out because if CK 7 is an effective marker for Paget cells, it is not 100% specific. Indeed, CK 7 is also a marker for Toker cells which are considered however for certain authors as precursors of Paget cell carcinoma [9].

In conclusion, in the present study, we have clearly demonstrated for the first time by double stain immunohistochemistry, that Paget cells have not only the same immunophenotype underlying intraductal carcinoma but also share similar proliferating properties [4].

References

- [1] Eusebi V., Mai K.T., Taranger-Charpin A.: "Tumours of the nipple". In: Tavassoli F.A., Devilee P. (eds.). World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of the Breast and Female Genital Organs. Lyon, IARC Press, 2003, 104.
- [2] Ellis I.O., Elston C.W., Poller D.N.: "Paget's disease of the nipple". In: Elston C.W., Ellis I.O. (eds.). The Breast. Edinburgh, Churchill Livingstone, 1998, 276.
- [3] Rosen P.P.: "Paget's disease of the nipple". In: Rosen P.P. (ed.). Rosen's Breast Pathology. Philadelphia, Lippincott Williams & Wilkins, 2001, 565.
- [4] Cohen I., Guarner J., DeRose P.B.: "Mammary Paget's disease and associated carcinoma. An immunohistochemical study". *Arch. Pathol. Lab. Med.*, 1993, 117, 291.
- [5] Fu W., Mittel V.K., Young S.C.: "Paget disease of the breast: analysis of 41 patients". *Am. J. Clin. Oncol.*, 2001, 24, 397.
- [6] Kothari A.S., Beechey-Newman N., Hamed H., Fentiman I.S., D'Arrigo C., Hanby A.M. *et al.*: "Paget disease of the nipple: a multifocal manifestation of higher-risk disease". *Cancer*, 2002, 95, 1.
- [7] Schelfhout V.R.J., Coene E.D., Delaey B., Thys S., Page D.L., De Potter C.R.: "Pathogenesis of Paget's disease: epidermal heregulin-alpha motility factor and the HER receptor family". *J. Natl. Cancer Inst.*, 2000, 92, 622.
- [8] De Potter C.R., Eeckhout I., Schelfhout A.M., Geerts M.L., Roels H.J.: "Keratinocyte induced chemotaxis in the pathogenesis of Paget's disease of the breast". *Histopathology*, 1994, 24, 349.
- [9] Marucci G., Betts C., Golouh R., Peterse J.L., Foschini M.P., Eusebi V.: "Toker cells are probably precursors of Paget cell carcinoma: a morphological and ultrastructural description". *Virchows Arch.*, 2002, 441, 117.
- [10] Lammie G.A., Barnes D.M., Millis R.R., Gullick W.J.: "An immunohistochemical study of the presence of c-erb-2 protein in Paget's disease of the nipple". *Histopathology*, 1989, 15, 505.
- [11] Keatings L., Sinclair J., Wright C., Corbett I.P., Watchorn C., Hennessy C. *et al.*: "C-erb-2 oncoprotein expression in mammary and extramammary Paget's disease". *Histopathology*, 1990, 17, 243.
- [12] Ellis P.E., Fong L.F., Rolfe K.J., Crow J.C., Reid W.M., Davidson T. *et al.*: "The role of p53 and Ki67 in Paget's disease of the vulva and the breast". *Gynecol. Oncol.*, 2002, 86, 150.
- [13] Endl E., Gerdes J.: "The Ki-67 protein: fascinating forms of unknown function". *Exp. Cell. Res.*, 2000, 257, 231.
- [14] Noel J.C., Fayt I., Fernandez-Aguilar S., Buxant F., Boutemy R.: "Proliferating activity in columnar cells lesions of the breast". *Virchows Arch.*, 2006, 449, 617.
- [15] Heenen M., Thiriar S., Noel J.C., Galand P.: "Ki-67 immunostaining of normal human epidermis: comparison with 3H-thymidine labelling and PCNA immunostaining". *Dermatology*, 1998, 197, 123.
- [16] Elston C.W., Ellis I.O.: "Pathological prognostic factors in breast cancer. The value of histological grade in breast: experience from a large study with long-term follow-up". *Histopathology*, 1991, 19, 403.
- [17] Buxant F., Noel J.C.: "p16 expression in Paget's disease of the breast". *Eur. J. Gynaecol. Oncol.*, 2008, 24, 441.

Address reprint requests to:
F. BUXANT, M.D.
Gynecology Department
Erasmus Hospital
Route de Lennik 808
1070 Brussels (Belgium)
e-mail: Fbuxant@ulb.ac.be